A quick note on Q3 venture life-science data
An item on the third-quarter life-science venture data I’d initially planned to update over the weekend got unavoidably delayed, but is now available in updated form. At the risk of ruining the suspense, the major surprise is that venture capitalists appear to be abandoning the biotech sector in droves, with private equity and other non-VC sources of cash picking up the slack.
Next Story: Voltage raises $12M more for encryption technology
Previous Story: Battelle Ventures invests $8M in cleantech startups
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.
